Combining ability analysis for yield and quality traits in single cross hybrids of quality protein maize (Zea mays L.) using diallel mating design

Forty-five single-cross hybrids developed (in rabi 2014) from ten inbred lines of quality protein maize through diallel mating design along with four checks viz., Pratap QPM Hybrid- 1, Vivek QPM- 9, HQPM- 1 and HQPM-5 were evaluated in randomized block design with three replications for yield and quality traits during kharif-2014, to estimate the gca (general combining ability) of the parents and sca (specific combining ability) of hybrids considered for the development of high yielding varieties. The analysis of variance for combining ability revealed significant mean sum of squares due to gca and sca for all the traits, except mean sum of square due to gca for num-ber of grain rows per ear. Ratio of ?2 sca / ? 2 gca was greater than one for all the traits, thereby indicating the preponderance of non-additive gene effects in the expression of these traits. Inbred line P8 and P5 has been found good general combiner with highest magnitude of gca effects 10.46 and 8.89, respectively and high per se i.e. 52.33 g and 44.67 g, respectively for grain yield per plant and majority of traits. Hybrids P6xP8, P5xP8, P3xP5, P5xP7 and P1xP8 showed higher significant positive sca effects ranged from 25.66 to 34.59 along with good per se ranged from 98.00 to 107.67 g for grain yield per plant. These hybrids also exhibited significant positive sca effects for most of the yield and quality traits under study, indicating potential and may be used for exploiting hybrid vigour in in QPM hybrid breeding programmes

Coronavirus Disease 2019 (COVID-19): Origin, Impact, and Drug Development

At the end of December 2019, in Wuhan, China, a rapidly spreading unknown virus was reported to have caused coronavirus disease of 2019 (COVID-19). Origin linked to Wuhan’s wholesale food market where live animals are sold. This disease is caused by SARS Coronavirus-2 (SARS-CoV-2), which is closely related to the Severe Acute Respiratory Coronavirus (SARS-CoV) and the Middle East Respiratory Syndrome Coronavirus (MERS-CoV). This virus shares a high sequence identity with bat-derived SARS-like Coronavirus, which indicating its zoonotic origin. The virus spread globally, provoking widespread attention and panic. This Coronavirus is highly pathogenic and causes mild to severe respiratory disorders. Later, it was declared a global pandemic by the World Health Organization (WHO) due to its highly infectious nature and worldwide mortality rate. This virus is a single-stranded, positive-sense RNA genome, and its genome length about 26 to 32 kb that infects a broad range of vertebrates. The researchers worldwide focus on establishing treatment strategies on drug and vaccine development to prevent this COVID-19 pandemic. A drug repurposing approach has been used to identify a rapid treatment for the people affected by COVID-19, which could be cost-effective and bypass some Food and Drug Association (FDA) regulations to move quickly in phase-3 trials. However, there is no promising therapeutic option available yet. This book chapter addresses current information about the COVID-19 disease, including its origins, impacts, and the novel potential drug candidates that can help treat the COVID-19

A randomised controlled trial to compare the efficacy, safety, and tolerability of low dose, short course primaquine in adults with uncomplicated P. vivax malaria in two hospitals in India

Background: Plasmodium vivax remains a major challenge for malaria control and elimination due to its ability to cause relapsing illness. To prevent relapses the Indian National Center for Vector Borne Diseases Control (NCVBDC) recommends treatment with primaquine at a dose of 0.25 mg/kg/day provided over 14 days. Shorter treatment courses may improve adherence and treatment effectiveness. Methods: This is a hospital-based, randomised, controlled, open-label trial in two centres in India. Patients above the age of 16 years, with uncomplicated vivax malaria, G6PD activity of ≥ 30% of the adjusted male median (AMM) and haemoglobin levels ≥ 8 g/dL will be recruited into the study and randomised in a 1:1 ratio to receive standard schizonticidal treatment plus 7-day primaquine at 0.50 mg/kg/day or standard care with schizonticidal treatment plus 14-day primaquine at 0.25 mg/kg/day. Patients will be followed up for 6 months. The primary endpoint is the incidence risk of any P. vivax parasitaemia at 6 months. Safety outcomes include the incidence risk of severe anaemia (haemoglobin 25% fall in haemoglobin and an acute drop in haemoglobin of > 5 g/dL during primaquine treatment. Discussion: This study will evaluate the efficacy and safety of a 7-day primaquine regimen compared to the standard 14-day regimen in India. Results from this trial are likely to directly inform national treatment guidelines. Trial registration: Trial is registered on CTRI portal, Registration No: CTRI/2022/12/048283

Impact of COVID-19 on cardiovascular testing in the United States versus the rest of the world

Objectives: This study sought to quantify and compare the decline in volumes of cardiovascular procedures between the United States and non-US institutions during the early phase of the coronavirus disease-2019 (COVID-19) pandemic. Background: The COVID-19 pandemic has disrupted the care of many non-COVID-19 illnesses. Reductions in diagnostic cardiovascular testing around the world have led to concerns over the implications of reduced testing for cardiovascular disease (CVD) morbidity and mortality. Methods: Data were submitted to the INCAPS-COVID (International Atomic Energy Agency Non-Invasive Cardiology Protocols Study of COVID-19), a multinational registry comprising 909 institutions in 108 countries (including 155 facilities in 40 U.S. states), assessing the impact of the COVID-19 pandemic on volumes of diagnostic cardiovascular procedures. Data were obtained for April 2020 and compared with volumes of baseline procedures from March 2019. We compared laboratory characteristics, practices, and procedure volumes between U.S. and non-U.S. facilities and between U.S. geographic regions and identified factors associated with volume reduction in the United States. Results: Reductions in the volumes of procedures in the United States were similar to those in non-U.S. facilities (68% vs. 63%, respectively; p = 0.237), although U.S. facilities reported greater reductions in invasive coronary angiography (69% vs. 53%, respectively; p < 0.001). Significantly more U.S. facilities reported increased use of telehealth and patient screening measures than non-U.S. facilities, such as temperature checks, symptom screenings, and COVID-19 testing. Reductions in volumes of procedures differed between U.S. regions, with larger declines observed in the Northeast (76%) and Midwest (74%) than in the South (62%) and West (44%). Prevalence of COVID-19, staff redeployments, outpatient centers, and urban centers were associated with greater reductions in volume in U.S. facilities in a multivariable analysis. Conclusions: We observed marked reductions in U.S. cardiovascular testing in the early phase of the pandemic and significant variability between U.S. regions. The association between reductions of volumes and COVID-19 prevalence in the United States highlighted the need for proactive efforts to maintain access to cardiovascular testing in areas most affected by outbreaks of COVID-19 infection

Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021

Background: Understanding the health consequences associated with exposure to risk factors is necessary to inform public health policy and practice. To systematically quantify the contributions of risk factor exposures to specific health outcomes, the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021 aims to provide comprehensive estimates of exposure levels, relative health risks, and attributable burden of disease for 88 risk factors in 204 countries and territories and 811 subnational locations, from 1990 to 2021. Methods: The GBD 2021 risk factor analysis used data from 54 561 total distinct sources to produce epidemiological estimates for 88 risk factors and their associated health outcomes for a total of 631 risk–outcome pairs. Pairs were included on the basis of data-driven determination of a risk–outcome association. Age-sex-location-year-specific estimates were generated at global, regional, and national levels. Our approach followed the comparative risk assessment framework predicated on a causal web of hierarchically organised, potentially combinative, modifiable risks. Relative risks (RRs) of a given outcome occurring as a function of risk factor exposure were estimated separately for each risk–outcome pair, and summary exposure values (SEVs), representing risk-weighted exposure prevalence, and theoretical minimum risk exposure levels (TMRELs) were estimated for each risk factor. These estimates were used to calculate the population attributable fraction (PAF; ie, the proportional change in health risk that would occur if exposure to a risk factor were reduced to the TMREL). The product of PAFs and disease burden associated with a given outcome, measured in disability-adjusted life-years (DALYs), yielded measures of attributable burden (ie, the proportion of total disease burden attributable to a particular risk factor or combination of risk factors). Adjustments for mediation were applied to account for relationships involving risk factors that act indirectly on outcomes via intermediate risks. Attributable burden estimates were stratified by Socio-demographic Index (SDI) quintile and presented as counts, age-standardised rates, and rankings. To complement estimates of RR and attributable burden, newly developed burden of proof risk function (BPRF) methods were applied to yield supplementary, conservative interpretations of risk–outcome associations based on the consistency of underlying evidence, accounting for unexplained heterogeneity between input data from different studies. Estimates reported represent the mean value across 500 draws from the estimate's distribution, with 95% uncertainty intervals (UIs) calculated as the 2·5th and 97·5th percentile values across the draws. Findings: Among the specific risk factors analysed for this study, particulate matter air pollution was the leading contributor to the global disease burden in 2021, contributing 8·0% (95% UI 6·7–9·4) of total DALYs, followed by high systolic blood pressure (SBP; 7·8% [6·4–9·2]), smoking (5·7% [4·7–6·8]), low birthweight and short gestation (5·6% [4·8–6·3]), and high fasting plasma glucose (FPG; 5·4% [4·8–6·0]). For younger demographics (ie, those aged 0–4 years and 5–14 years), risks such as low birthweight and short gestation and unsafe water, sanitation, and handwashing (WaSH) were among the leading risk factors, while for older age groups, metabolic risks such as high SBP, high body-mass index (BMI), high FPG, and high LDL cholesterol had a greater impact. From 2000 to 2021, there was an observable shift in global health challenges, marked by a decline in the number of all-age DALYs broadly attributable to behavioural risks (decrease of 20·7% [13·9–27·7]) and environmental and occupational risks (decrease of 22·0% [15·5–28·8]), coupled with a 49·4% (42·3–56·9) increase in DALYs attributable to metabolic risks, all reflecting ageing populations and changing lifestyles on a global scale. Age-standardised global DALY rates attributable to high BMI and high FPG rose considerably (15·7% [9·9–21·7] for high BMI and 7·9% [3·3–12·9] for high FPG) over this period, with exposure to these risks increasing annually at rates of 1·8% (1·6–1·9) for high BMI and 1·3% (1·1–1·5) for high FPG. By contrast, the global risk-attributable burden and exposure to many other risk factors declined, notably for risks such as child growth failure and unsafe water source, with age-standardised attributable DALYs decreasing by 71·5% (64·4–78·8) for child growth failure and 66·3% (60·2–72·0) for unsafe water source. We separated risk factors into three groups according to trajectory over time: those with a decreasing attributable burden, due largely to declining risk exposure (eg, diet high in trans-fat and household air pollution) but also to proportionally smaller child and youth populations (eg, child and maternal malnutrition); those for which the burden increased moderately in spite of declining risk exposure, due largely to population ageing (eg, smoking); and those for which the burden increased considerably due to both increasing risk exposure and population ageing (eg, ambient particulate matter air pollution, high BMI, high FPG, and high SBP). Interpretation: Substantial progress has been made in reducing the global disease burden attributable to a range of risk factors, particularly those related to maternal and child health, WaSH, and household air pollution. Maintaining efforts to minimise the impact of these risk factors, especially in low SDI locations, is necessary to sustain progress. Successes in moderating the smoking-related burden by reducing risk exposure highlight the need to advance policies that reduce exposure to other leading risk factors such as ambient particulate matter air pollution and high SBP. Troubling increases in high FPG, high BMI, and other risk factors related to obesity and metabolic syndrome indicate an urgent need to identify and implement interventions

Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021

BACKGROUND Regular, detailed reporting on population health by underlying cause of death is fundamental for public health decision making. Cause-specific estimates of mortality and the subsequent effects on life expectancy worldwide are valuable metrics to gauge progress in reducing mortality rates. These estimates are particularly important following large-scale mortality spikes, such as the COVID-19 pandemic. When systematically analysed, mortality rates and life expectancy allow comparisons of the consequences of causes of death globally and over time, providing a nuanced understanding of the effect of these causes on global populations. METHODS The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021 cause-of-death analysis estimated mortality and years of life lost (YLLs) from 288 causes of death by age-sex-location-year in 204 countries and territories and 811 subnational locations for each year from 1990 until 2021. The analysis used 56 604 data sources, including data from vital registration and verbal autopsy as well as surveys, censuses, surveillance systems, and cancer registries, among others. As with previous GBD rounds, cause-specific death rates for most causes were estimated using the Cause of Death Ensemble model-a modelling tool developed for GBD to assess the out-of-sample predictive validity of different statistical models and covariate permutations and combine those results to produce cause-specific mortality estimates-with alternative strategies adapted to model causes with insufficient data, substantial changes in reporting over the study period, or unusual epidemiology. YLLs were computed as the product of the number of deaths for each cause-age-sex-location-year and the standard life expectancy at each age. As part of the modelling process, uncertainty intervals (UIs) were generated using the 2·5th and 97·5th percentiles from a 1000-draw distribution for each metric. We decomposed life expectancy by cause of death, location, and year to show cause-specific effects on life expectancy from 1990 to 2021. We also used the coefficient of variation and the fraction of population affected by 90% of deaths to highlight concentrations of mortality. Findings are reported in counts and age-standardised rates. Methodological improvements for cause-of-death estimates in GBD 2021 include the expansion of under-5-years age group to include four new age groups, enhanced methods to account for stochastic variation of sparse data, and the inclusion of COVID-19 and other pandemic-related mortality-which includes excess mortality associated with the pandemic, excluding COVID-19, lower respiratory infections, measles, malaria, and pertussis. For this analysis, 199 new country-years of vital registration cause-of-death data, 5 country-years of surveillance data, 21 country-years of verbal autopsy data, and 94 country-years of other data types were added to those used in previous GBD rounds. FINDINGS The leading causes of age-standardised deaths globally were the same in 2019 as they were in 1990; in descending order, these were, ischaemic heart disease, stroke, chronic obstructive pulmonary disease, and lower respiratory infections. In 2021, however, COVID-19 replaced stroke as the second-leading age-standardised cause of death, with 94·0 deaths (95% UI 89·2-100·0) per 100 000 population. The COVID-19 pandemic shifted the rankings of the leading five causes, lowering stroke to the third-leading and chronic obstructive pulmonary disease to the fourth-leading position. In 2021, the highest age-standardised death rates from COVID-19 occurred in sub-Saharan Africa (271·0 deaths [250·1-290·7] per 100 000 population) and Latin America and the Caribbean (195·4 deaths [182·1-211·4] per 100 000 population). The lowest age-standardised death rates from COVID-19 were in the high-income super-region (48·1 deaths [47·4-48·8] per 100 000 population) and southeast Asia, east Asia, and Oceania (23·2 deaths [16·3-37·2] per 100 000 population). Globally, life expectancy steadily improved between 1990 and 2019 for 18 of the 22 investigated causes. Decomposition of global and regional life expectancy showed the positive effect that reductions in deaths from enteric infections, lower respiratory infections, stroke, and neonatal deaths, among others have contributed to improved survival over the study period. However, a net reduction of 1·6 years occurred in global life expectancy between 2019 and 2021, primarily due to increased death rates from COVID-19 and other pandemic-related mortality. Life expectancy was highly variable between super-regions over the study period, with southeast Asia, east Asia, and Oceania gaining 8·3 years (6·7-9·9) overall, while having the smallest reduction in life expectancy due to COVID-19 (0·4 years). The largest reduction in life expectancy due to COVID-19 occurred in Latin America and the Caribbean (3·6 years). Additionally, 53 of the 288 causes of death were highly concentrated in locations with less than 50% of the global population as of 2021, and these causes of death became progressively more concentrated since 1990, when only 44 causes showed this pattern. The concentration phenomenon is discussed heuristically with respect to enteric and lower respiratory infections, malaria, HIV/AIDS, neonatal disorders, tuberculosis, and measles. INTERPRETATION Long-standing gains in life expectancy and reductions in many of the leading causes of death have been disrupted by the COVID-19 pandemic, the adverse effects of which were spread unevenly among populations. Despite the pandemic, there has been continued progress in combatting several notable causes of death, leading to improved global life expectancy over the study period. Each of the seven GBD super-regions showed an overall improvement from 1990 and 2021, obscuring the negative effect in the years of the pandemic. Additionally, our findings regarding regional variation in causes of death driving increases in life expectancy hold clear policy utility. Analyses of shifting mortality trends reveal that several causes, once widespread globally, are now increasingly concentrated geographically. These changes in mortality concentration, alongside further investigation of changing risks, interventions, and relevant policy, present an important opportunity to deepen our understanding of mortality-reduction strategies. Examining patterns in mortality concentration might reveal areas where successful public health interventions have been implemented. Translating these successes to locations where certain causes of death remain entrenched can inform policies that work to improve life expectancy for people everywhere. FUNDING Bill & Melinda Gates Foundation

Global, regional, and national burden of disorders affecting the nervous system, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021

BackgroundDisorders affecting the nervous system are diverse and include neurodevelopmental disorders, late-life neurodegeneration, and newly emergent conditions, such as cognitive impairment following COVID-19. Previous publications from the Global Burden of Disease, Injuries, and Risk Factor Study estimated the burden of 15 neurological conditions in 2015 and 2016, but these analyses did not include neurodevelopmental disorders, as defined by the International Classification of Diseases (ICD)-11, or a subset of cases of congenital, neonatal, and infectious conditions that cause neurological damage. Here, we estimate nervous system health loss caused by 37 unique conditions and their associated risk factors globally, regionally, and nationally from 1990 to 2021.MethodsWe estimated mortality, prevalence, years lived with disability (YLDs), years of life lost (YLLs), and disability-adjusted life-years (DALYs), with corresponding 95% uncertainty intervals (UIs), by age and sex in 204 countries and territories, from 1990 to 2021. We included morbidity and deaths due to neurological conditions, for which health loss is directly due to damage to the CNS or peripheral nervous system. We also isolated neurological health loss from conditions for which nervous system morbidity is a consequence, but not the primary feature, including a subset of congenital conditions (ie, chromosomal anomalies and congenital birth defects), neonatal conditions (ie, jaundice, preterm birth, and sepsis), infectious diseases (ie, COVID-19, cystic echinococcosis, malaria, syphilis, and Zika virus disease), and diabetic neuropathy. By conducting a sequela-level analysis of the health outcomes for these conditions, only cases where nervous system damage occurred were included, and YLDs were recalculated to isolate the non-fatal burden directly attributable to nervous system health loss. A comorbidity correction was used to calculate total prevalence of all conditions that affect the nervous system combined.FindingsGlobally, the 37 conditions affecting the nervous system were collectively ranked as the leading group cause of DALYs in 2021 (443 million, 95% UI 378–521), affecting 3·40 billion (3·20–3·62) individuals (43·1%, 40·5–45·9 of the global population); global DALY counts attributed to these conditions increased by 18·2% (8·7–26·7) between 1990 and 2021. Age-standardised rates of deaths per 100 000 people attributed to these conditions decreased from 1990 to 2021 by 33·6% (27·6–38·8), and age-standardised rates of DALYs attributed to these conditions decreased by 27·0% (21·5–32·4). Age-standardised prevalence was almost stable, with a change of 1·5% (0·7–2·4). The ten conditions with the highest age-standardised DALYs in 2021 were stroke, neonatal encephalopathy, migraine, Alzheimer's disease and other dementias, diabetic neuropathy, meningitis, epilepsy, neurological complications due to preterm birth, autism spectrum disorder, and nervous system cancer.InterpretationAs the leading cause of overall disease burden in the world, with increasing global DALY counts, effective prevention, treatment, and rehabilitation strategies for disorders affecting the nervous system are needed

Propriétés électriques et optiques des nanofils uniques de silicium

In this work we present the characterization of the light absorption properties of single silicon NWs (NW) using photocurrent spectroscopy along with the preliminary work done at the wire scale to characterize the dopant incorporation and the fabrication of junctions. First, we start with a description of the growth methods used to synthesize active NW's for photocurrent generation, with results obtained on the use of hydrogen chloride in the CVD VLS growth of doped NWs. This method offers highly straight structures, widened process temperatures allowing in particular very efficient boron incorporation—ionized acceptors densities up to 1.8E19 cm-3—and inhibited gold diffusion, thereby greatly reducing elemental contamination from the catalyst. Focus is made on the junction formation, the study of its electrical characteristics and the influence of morphological parameters—radius, axial position—to obtain the desired doping properties. In a second part, we present the photocurrent response of a set of different diameter active Si NWs and correlate our results with an analytical treatment of the photon absorption at the nanoscale using the Lorentz Mie theory adapted to the cylindrical geometry under study. Very good agreement is found between experiment and theory for both polarization spectra (TE-TM). Absorption resonances are resolved, corresponding to leak resonant modes, and can display absorption efficiencies higher than one, making downscaling an efficient tool to increase energy harvesting capabilities. In a last part, we adapt the antireflective coating strategy used in solar cells to improve the coupling of the incoming light to Si NWs. For this, SiO2 and Si3N4 films are deposited on NWs using PECVD, providing a set of structures coated with a high level of conformity. Based on the new set of spectra we obtain the relative gain curves and compare them with analytical calculations specifically derived for getting the absorption in the core of coaxial nanocylinders only, which allows estimating the magnitude of the absorbed energy in the dielectric shell.Ce travail présente la caractérisation des propriétés d'absorption de lumière par des nanofils uniques (NF) de silicium en utilisant la spectroscopie de photocourant, ainsi qu'une étude préliminaire des processus d'incorporation des dopants et de réalisation de jonction dans les NFs. Tout d'abord, nous commençons par décrire les méthodes de croissance utilisées pour synthétiser des NFs actifs pour la génération de photocourant, avec l'utilisation du chlorure d'hydrogène dans les procédés classiques de croissance CVD catalysée or de fils dopés. Cette méthode offre des structures très faiblement coniques, élargit les températures de procédé, permettant en particulier d'incorporer très efficacement le bore, avec des densités d'accepteurs ionisés allant jusqu'à 1.8E19 cm-3, tout en inhibant la diffusion d'or depuis le catalyseur. L'attention est ensuite portée à la fabrication de jonctions, l'étude de ses caractéristiques électriques, ainsi que sur l'influence de paramètres morphologiques (rayon, position axiale) du fil sur sa résistivité apparente. Dans une seconde partie, nous étudions la réponse en photocourant d'un jeu de NFs actifs de différents diamètres et corrélons nos résultats à un traitement analytique de l'absorption des photons à l'échelle du nanoobjet dans le cadre de la théorie de Mie adaptée au cas cylindrique. L'accord expérience-théorie est très bon pour les deux polarisations (TE-TM). Des résonances dans le spectre d'absorption sont mises en évidence, correspondant à l'excitation de modes propres du fil, et associées à des sections efficaces d'absorption pouvant être supérieures à l'unité. Dans une dernière partie, nous adaptons la stratégie de dépôt antireflet utilisée dans les cellules solaires pour améliorer le couplage de la lumière incidente aux NFs. Pour cela, des dépôts de SiO2 et Si3N4 sont réalisés sur des NFs via la technique de PECVD, nous fournissant par là-même un jeu de structures pourvues d'un dépôt de diélectrique à haute conformité. Se basant sur les spectres d'absorption ainsi acquis, nous obtenons les gains relatifs d'absorption induits par le dépôt de diélectrique et les comparons aux calculs analytiques développés spécifiquement pour obtenir l'absorption dans le cœur seulement du cylindre coaxial, ceci nous permettant également d'estimer la partie du rayonnement incident absorbé dans la coquille diélectrique

Electrical and optical properties of single silicon nanowires

Ce travail présente la caractérisation des propriétés d'absorption de lumière par des nanofils uniques (NF) de silicium en utilisant la spectroscopie de photocourant, ainsi qu'une étude préliminaire des processus d'incorporation des dopants et de réalisation de jonction dans les NFs. Tout d'abord, nous commençons par décrire les méthodes de croissance utilisées pour synthétiser des NFs actifs pour la génération de photocourant, avec l'utilisation du chlorure d'hydrogène dans les procédés classiques de croissance CVD catalysée or de fils dopés. Cette méthode offre des structures très faiblement coniques, élargit les températures de procédé, permettant en particulier d'incorporer très efficacement le bore, avec des densités d'accepteurs ionisés allant jusqu'à 1.8E19 cm-3, tout en inhibant la diffusion d'or depuis le catalyseur. L'attention est ensuite portée à la fabrication de jonctions, l'étude de ses caractéristiques électriques, ainsi que sur l'influence de paramètres morphologiques (rayon, position axiale) du fil sur sa résistivité apparente. Dans une seconde partie, nous étudions la réponse en photocourant d'un jeu de NFs actifs de différents diamètres et corrélons nos résultats à un traitement analytique de l'absorption des photons à l'échelle du nanoobjet dans le cadre de la théorie de Mie adaptée au cas cylindrique. L'accord expérience-théorie est très bon pour les deux polarisations (TE-TM). Des résonances dans le spectre d'absorption sont mises en évidence, correspondant à l'excitation de modes propres du fil, et associées à des sections efficaces d'absorption pouvant être supérieures à l'unité. Dans une dernière partie, nous adaptons la stratégie de dépôt antireflet utilisée dans les cellules solaires pour améliorer le couplage de la lumière incidente aux NFs. Pour cela, des dépôts de SiO2 et Si3N4 sont réalisés sur des NFs via la technique de PECVD, nous fournissant par là-même un jeu de structures pourvues d'un dépôt de diélectrique à haute conformité. Se basant sur les spectres d'absorption ainsi acquis, nous obtenons les gains relatifs d'absorption induits par le dépôt de diélectrique et les comparons aux calculs analytiques développés spécifiquement pour obtenir l'absorption dans le cœur seulement du cylindre coaxial, ceci nous permettant également d'estimer la partie du rayonnement incident absorbé dans la coquille diélectrique.In this work we present the characterization of the light absorption properties of single silicon NWs (NW) using photocurrent spectroscopy along with the preliminary work done at the wire scale to characterize the dopant incorporation and the fabrication of junctions. First, we start with a description of the growth methods used to synthesize active NW's for photocurrent generation, with results obtained on the use of hydrogen chloride in the CVD VLS growth of doped NWs. This method offers highly straight structures, widened process temperatures allowing in particular very efficient boron incorporation—ionized acceptors densities up to 1.8E19 cm-3—and inhibited gold diffusion, thereby greatly reducing elemental contamination from the catalyst. Focus is made on the junction formation, the study of its electrical characteristics and the influence of morphological parameters—radius, axial position—to obtain the desired doping properties. In a second part, we present the photocurrent response of a set of different diameter active Si NWs and correlate our results with an analytical treatment of the photon absorption at the nanoscale using the Lorentz Mie theory adapted to the cylindrical geometry under study. Very good agreement is found between experiment and theory for both polarization spectra (TE-TM). Absorption resonances are resolved, corresponding to leak resonant modes, and can display absorption efficiencies higher than one, making downscaling an efficient tool to increase energy harvesting capabilities. In a last part, we adapt the antireflective coating strategy used in solar cells to improve the coupling of the incoming light to Si NWs. For this, SiO2 and Si3N4 films are deposited on NWs using PECVD, providing a set of structures coated with a high level of conformity. Based on the new set of spectra we obtain the relative gain curves and compare them with analytical calculations specifically derived for getting the absorption in the core of coaxial nanocylinders only, which allows estimating the magnitude of the absorbed energy in the dielectric shell